JW Therapeutics
IPO上海药明巨诺生物科技有限公司
- Headquarters
- Shanghai
- Employees
- 201–500
- Founded
- 2016
- Business Model
- B2B
- Website
- jwtherapeutics.com
- Total Funding
- $190.0M
- Last Round
- $100.0M Series BJun 2020
- Rounds
- 2
- Type
- Public
About
JW Therapeutics (HKEx: 2126) is an independent biotechnology company focused on developing, manufacturing, and commercializing cell immunotherapy products in China and globally. Founded in 2016 and headquartered in Shanghai, the company's flagship product Carteyva® (relma-cel) is an approved anti-CD19 CAR-T therapy for relapsed/refractory large B-cell lymphoma. Its pipeline spans hematologic malignancies, solid tumors, and autoimmune diseases.
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingSign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Investors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free AccountSimilar Companies
Biopharmaceutical services company
Specialty pharmaceutical company
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...